Drug Res (Stuttg) 2014; 64(S 01): S24
DOI: 10.1055/s-0033-1358038
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

M/XDR-Tuberculosis: Therapy as Prevention

C. Lange
1  Forschungszentrum Borstel
2  Universität Lübeck
3  Karolinska Institut, Stockholm, Schweden
4  Universität von Namibia, Windhoek, Namibia
› Author Affiliations
Further Information

Publication History

Publication Date:
25 November 2014 (online)

As the incidence of tuberculosis (TB) has been globally declining over the past decades the World Health Organization (WHO) is now proposing the elimination of TB in Europe. However, in the absence of an effective vaccine for the prevention of TB, elimination of TB will not be possible in the near future due to the emergence of drug-resistant strains of Mycobacterium tuberculosis. Forty-four percent of all patients identified with multidrug-resistant or extensively drug-resistant tuberculosis (MDR-TB, XDR-TB) worldwide live in the European Region of the WHO. Management and prognosis of patients with M/XDR-TB is dramatically different from patients with pan drug-susceptible TB in several ways.